ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc (FDMT)

4.55
-0.17
( -3.60% )
Updated: 03:51:44

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.55
Bid
4.55
Offer
4.57
Volume
164,653
4.50 Day's Range 4.735
4.48 52 Week Range 36.25
Market Cap
Previous Close
4.72
Open
4.72
Last Trade
1
@
4.5644
Last Trade Time
03:52:16
Financial Volume
US$ 756,400
VWAP
4.5939
Average Volume (3m)
901,842
Shares Outstanding
46,227,709
Dividend Yield
-
PE Ratio
-2.10
Earnings Per Share (EPS)
-2.18
Revenue
20.72M
Net Profit
-100.84M

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
4D Molecular Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker FDMT. The last closing price for 4D Molecular Therapeutics was US$4.72. Over the last year, 4D Molecular Therapeutics shares have traded in a share price range of US$ 4.48 to US$ 36.25.

4D Molecular Therapeutics currently has 46,227,709 shares in issue. The market capitalisation of 4D Molecular Therapeutics is US$218.19 million. 4D Molecular Therapeutics has a price to earnings ratio (PE ratio) of -2.10.

FDMT Latest News

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic...

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.015-0.3285870755754.5654.9554.485842354.66790685CS
4-0.77-14.47368421055.326.6664.487766525.28646157CS
12-3.79-45.44364508398.349.17994.489018426.68544905CS
26-13.83-75.244831338418.3818.384.488123519.51070164CS
52-13.38-74.623535973217.9336.254.4892000918.67040654CS
156-9.58-67.799009200314.1336.254.4855484717.37247236CS
260-35.45-88.6254055.114.4845598018.88548746CS

FDMT - Frequently Asked Questions (FAQ)

What is the current 4D Molecular Therapeutics share price?
The current share price of 4D Molecular Therapeutics is US$ 4.55
How many 4D Molecular Therapeutics shares are in issue?
4D Molecular Therapeutics has 46,227,709 shares in issue
What is the market cap of 4D Molecular Therapeutics?
The market capitalisation of 4D Molecular Therapeutics is USD 218.19M
What is the 1 year trading range for 4D Molecular Therapeutics share price?
4D Molecular Therapeutics has traded in the range of US$ 4.48 to US$ 36.25 during the past year
What is the PE ratio of 4D Molecular Therapeutics?
The price to earnings ratio of 4D Molecular Therapeutics is -2.1
What is the cash to sales ratio of 4D Molecular Therapeutics?
The cash to sales ratio of 4D Molecular Therapeutics is 10.19
What is the reporting currency for 4D Molecular Therapeutics?
4D Molecular Therapeutics reports financial results in USD
What is the latest annual turnover for 4D Molecular Therapeutics?
The latest annual turnover of 4D Molecular Therapeutics is USD 20.72M
What is the latest annual profit for 4D Molecular Therapeutics?
The latest annual profit of 4D Molecular Therapeutics is USD -100.84M
What is the registered address of 4D Molecular Therapeutics?
The registered address for 4D Molecular Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the 4D Molecular Therapeutics website address?
The website address for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com
Which industry sector does 4D Molecular Therapeutics operate in?
4D Molecular Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SLXNSilexion Therapeutics Corporation
US$ 1.2174
(109.90%)
175.96M
RNAZTransCode Therapeutics Inc
US$ 12.00
(75.70%)
18.01M
YIBOPlanet Image International Ltd
US$ 4.96
(61.04%)
48.81M
BACKIMAC Holdings Inc
US$ 1.169
(41.01%)
52.81M
RFACRF Acquisition Corporation
US$ 6.91
(38.20%)
61.05k
LPTXLeap Therapeutics Inc
US$ 0.6395
(-71.58%)
8.11M
STSSSharps Technology Inc
US$ 0.4361
(-70.13%)
11.78M
SABSSAB Biotherapeutics Inc
US$ 2.205
(-49.43%)
940.79k
MGOLMGO Global Inc
US$ 0.1751
(-38.13%)
14.79M
INKTMiNK Therapeutics Inc
US$ 6.4159
(-27.41%)
67.48k
NVDANVIDIA Corporation
US$ 121.48
(2.58%)
249.48M
HEPAHepion Pharmaceuticals Inc
US$ 0.2232
(35.27%)
233.22M
SLXNSilexion Therapeutics Corporation
US$ 1.2136
(109.24%)
175.96M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.5085
(23.39%)
135.5M
TRIBTrinity Biotech PLC
US$ 1.0496
(38.11%)
98.92M